Thromboembolic diseases are the leading causes of morbidity and mortality in the
developed world. Anticoagulants provide effective treatment for venous or arterial …

Introduction: Thrombosis is a common causal pathology for stroke, acute coronary syndrome
and venous thromboembolism disorders, which are the leading cause of death worldwide …

Factor Xa (fXa) is a key enzyme in the coagulation cascade and an essential component of
the prothrombinase complex, which activates prothrombin to thrombin, leading to fibrin clot …

Development of new anticoagulants has been in constant demand throughout the world due
to increasing rate of morbidity and mortality caused by thrombotic diseases. Factor Xa (FXa) …

Importance of the field. New oral anticoagulants with favorable safety profiles and fixed
doses are required for the management of thromboembolism and stroke prevention in …

Oral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This
paper reviews the latest developments of oral direct FXa inhibitors and focuses on those …

Novel anticoagulants to replace unfractionated heparins, low molecular weight heparins and
vitamin K antagonists, are needed urgently. Coagulation factor Xa is an attractive target for …

Thrombosis is a leading cause of death in cardiovascular diseases such as myocardial
infarction (MI), unstable angina and acute coronary syndrome (ACS) in the industrialized …

Ischemic heart disease and cerebrovascular disease are the leading causes of death in the
world. Surprisingly, these diseases are treated by relatively antiquated drugs. However, due …

Anticoagulant use is recommended for the prevention and treatment of several
thromboembolic disorders including venous thromboembolism. However, anticoagulants …